@Article{biocell.2024.052625,
AUTHOR = {XIAOXIAO HE, XUEQING ZHOU, JINPENG ZHANG, MINGFEI ZHANG, DANHONG ZENG, HENG ZHANG, SHUCAI YANG},
TITLE = {Apatinib reduces liver cancer cell multidrug resistance by modulating NF-κB signaling pathway},
JOURNAL = {BIOCELL},
VOLUME = {48},
YEAR = {2024},
NUMBER = {9},
PAGES = {1331--1341},
URL = {http://www.techscience.com/biocell/v48n9/57814},
ISSN = {1667-5746},
ABSTRACT = { <b>Objectives:</b> This investigation aimed to elucidate the inhibitory impact of apatinib on the multidrug resistance of liver cancer both <i>in vivo</i> and <i>in vitro</i>. <b>Methods:</b> To establish a Hep3B/5-Fu resistant cell line, 5-Fu concentrations were gradually increased in the culture media. Hep3B/5-Fu cells drug resistance and its alleviation by apatinib were confirmed via flow cytometry and Cell Counting Kit 8 (CCK8) test. Further, Nuclear factor kappa B (NF-κB) siRNA was transfected into Hep3B/5-Fu cells to assess alterations in the expression of multidrug resistance (MDR)-related genes and proteins. Nude mice were injected with Hep3B/5-Fu cells to establish subcutaneous xenograft tumors and then categorized into 8 treatment groups. The treatments included oxaliplatin, 5-Fu, and apatinib. In the tumor tissues, the expression of MDR-related genes was elucidated via qRT-PCR, immunohistochemistry, and Western blot analyses. <b>Results:</b> The apatinib-treated mice indicated slower tumor growth with smaller size compared to the control group. Both the <i>in vivo</i> and <i>in vitro</i> investigations revealed that the apatinib-treated groups had reduced expression of MDR genes GST-pi, LRP, MDR1, and p-p65. <b>Conclusions:</b> Apatinib effectively suppresses MDR in human hepatic cancer cells by modulating the expression of genes related to MDR, potentially by suppressing the NF-κB signaling pathway.},
DOI = {10.32604/biocell.2024.052625}
}